2-(morpholin-4-yl)-N-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenyl)benzenesulfonamide | 1333940-41-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-(morpholin-4-yl)-N-(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}phenyl)benzenesulfonamide
• 英文别名: 1-[4-[(2-Morpholin-4-ylphenyl)sulfonylamino]phenyl]-3-(pyridin-3-ylmethyl)urea
• CAS: 1333940-41-2
• 化学式: C₂₃H₂₅N₅O₄S
• 分子量: 467.549
• InChiKey: SQKHHPVCLRLNFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20150353538A1

  公开（公告）日：2015-12-10

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.
• THERAPEUTIC AND DIAGNOSTIC METHODS
  申请人：Fleischer Tracey C.

  公开号：US20160367541A1

  公开（公告）日：2016-12-22

  The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
• US8912184B1
  申请人：——

  公开号：US8912184B1

  公开（公告）日：2014-12-16